The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis

Clinical Infectious Diseases

Volumn 41, Issue 9, 2005, Pages 1232-1239

  Zaoutis, Theoklis E ^a,c   Argon, Jesse ^a   Chu, Jaclyn ^a   Berlin, Jesse A ^c,e   Walsh, Thomas J ^d   Feudtner, Chris ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANDIDA; CANDIDEMIA; CONTROLLED STUDY; COST OF ILLNESS; EXPOSURE; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

AGED; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; FUNGEMIA; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 27444432361     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/496922     Document Type: Article

References (36)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
3. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662-78.
4. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-89.
5. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.
6. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85:386-90.
7. Hallahan AR, Shaw PJ, Rowell G, O'Connell A, Schell D, Gillis J. Improved outcomes of children with malignancy admitted to a pediatric intensive care unit. Crit Care Med 2000; 28:3718-21.
8. Tenner PA, Dibrell H, Taylor RP. Improved survival with hospitalists in a pediatric intensive care unit. Crit Care Med 2003; 31:847-52.
9. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-43.
10. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-5.
11. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
12. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-8.
13. Project HaCU. Kids' inpatient database (KID), 2000 [database on CD-ROM]. Rockville, MD: Agency for Healthcare Research and Quality, 2002.
14. Feudtner C, Christakis DA, Zimmerman FJ, Muldoon JH, Neff JM, Koepsell TD. Characteristics of deaths occurring in children's hospitals: implications for supportive care services. Pediatrics 2002; 109:887-93.
15. Elixhauser A, Andrews R, Fox S. Clinical classifications for health policy research: discharge statistics by principal diagnosis and procedure. Bethesda, MD: Agency for Healthcare Research and Quality, 1993.
16. Offit PA, Peter G. The meningococcal vaccine-public policy and individual choices. N Engl J Med 2003; 349:2353-6.
17. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20:1531-4.
18. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia study group and the National Institute. N Engl J Med 1994; 331:1325-30.
19. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
20. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319-24.
21. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571-5.
22. Rodriguez-Nunez A. Incidence and mortality of proven invasive Candida infections in pediatric intensive care patients. Infect Control Hosp Epidemiol 2001; 22:477-8.
23. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26:642-5.
24. Turner RB, Donowitz LG, Hendley JO. Consequences of candidemia for pediatric patients. Am J Dis Child 1985; 139:178-80.
25. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701.
26. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003; 290: 1868-74.
27. Rosamond WD, Chambless LE, Sorlie PD, et al. Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. Am J Epidemiol 2004; 160:1137-46.
28. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
29. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-6.
30. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23:635-41.
31. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
32. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
33. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-6.
34. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-8.
35. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
36. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-200.